Obesity Featured Articles

31. How To Establish Strategic Readiness For First-In-Human Trials 4/29/2026

    Most teams realize too late that sequential planning creates delays. FIH readiness depends on aligning IND and clinical strategy early; otherwise, programs risk setbacks that stall execution and timelines.

32. Clinical Failures Persist Because They're Structural, Not Random 4/29/2026

    Clinical failures are no longer contained within a single program but happen across portfolios, companies, and therapeutic areas. Advisor Mikail Evteev suggests the reason is a failure to learn from past mistakes.

33. AI Won't Fix Clinical Development Until Pharma Changes How They Use It 4/28/2026

    Clinical development teams can unlock real AI value by aligning it to roles, workflows, and accountability. A practical operating model shows how to cut cycle time, reduce rework, and strengthen GxP‑ready decisions.

34. Understanding Subjective Outcome Measures In HAP Studies 4/28/2026

    Understanding how a participant "feels" is essential for drug safety. Explore how subjective measures and specialized training provide the data needed to evaluate human abuse potential.

35. Statistical Analysis In Human Abuse Potential Studies 4/28/2026

    Gain clarity on the rigorous statistical frameworks and E_max endpoint analyses required to evaluate drug abuse potential and satisfy complex regulatory safety standards.

36. Human-In-The-Loop In AI Validation And Control: From Principle To Practice 4/28/2026

    Explores how human-in-the-loop oversight can move from principle to practice. with a risk-based framework for determining when HITL is required, how the human role should be defined, and what organizational factors influence its effectiveness.

37. From Bench To Breakthrough: How Custom Kitting Fuels Precision Trials 4/27/2026

    Reduce trial variability and ensure protocol compliance with standardized custom kitting that transforms complex sample collection into a streamlined, strategic advantage for clinical success.

38. Static Reimbursement Structures Aren't Enough. Patients Need Whole-Person Support 4/27/2026

    Fixed patient reimbursement isn't enough, says Donna Libretti Cooke, Erin Miller, and Jeanne M. Regnante. To truly care for patients and support their participation in a clinical trial, they need whole-person support.

39. Breaking Barriers In Rare Disease Clinical Trials 4/27/2026

    Priovant Therapeutics CEO Ben Zimmer shares lessons learned from rare disease VALOR trial exploring a new therapy for the treatment of dermatomyositis.

40. Reimagining Data Governance For The AI Era 4/24/2026

    Understand the persistent governance challenges that undermine AI initiatives and walk away with a robust blueprint for building a resilient, scalable, and ethically sound framework.